全文获取类型
收费全文 | 96121篇 |
免费 | 9370篇 |
国内免费 | 5652篇 |
专业分类
耳鼻咽喉 | 117篇 |
儿科学 | 4057篇 |
妇产科学 | 386篇 |
基础医学 | 7681篇 |
口腔科学 | 518篇 |
临床医学 | 8506篇 |
内科学 | 24430篇 |
皮肤病学 | 630篇 |
神经病学 | 1566篇 |
特种医学 | 3252篇 |
外国民族医学 | 20篇 |
外科学 | 24418篇 |
综合类 | 15014篇 |
现状与发展 | 31篇 |
一般理论 | 2篇 |
预防医学 | 2815篇 |
眼科学 | 1275篇 |
药学 | 6862篇 |
38篇 | |
中国医学 | 4544篇 |
肿瘤学 | 4981篇 |
出版年
2024年 | 173篇 |
2023年 | 1622篇 |
2022年 | 2134篇 |
2021年 | 3695篇 |
2020年 | 3794篇 |
2019年 | 3615篇 |
2018年 | 3601篇 |
2017年 | 3699篇 |
2016年 | 4054篇 |
2015年 | 3718篇 |
2014年 | 6115篇 |
2013年 | 6432篇 |
2012年 | 5163篇 |
2011年 | 6076篇 |
2010年 | 5029篇 |
2009年 | 4983篇 |
2008年 | 5102篇 |
2007年 | 5316篇 |
2006年 | 5250篇 |
2005年 | 4537篇 |
2004年 | 3666篇 |
2003年 | 3160篇 |
2002年 | 2667篇 |
2001年 | 2351篇 |
2000年 | 1987篇 |
1999年 | 1582篇 |
1998年 | 1466篇 |
1997年 | 1281篇 |
1996年 | 1176篇 |
1995年 | 981篇 |
1994年 | 1031篇 |
1993年 | 698篇 |
1992年 | 789篇 |
1991年 | 584篇 |
1990年 | 476篇 |
1989年 | 422篇 |
1988年 | 407篇 |
1987年 | 308篇 |
1986年 | 263篇 |
1985年 | 299篇 |
1984年 | 246篇 |
1983年 | 151篇 |
1982年 | 188篇 |
1981年 | 159篇 |
1980年 | 130篇 |
1979年 | 109篇 |
1978年 | 111篇 |
1977年 | 90篇 |
1976年 | 100篇 |
1975年 | 43篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
41.
42.
器官移植术是20世纪出现的针对器官功能衰竭的最有效治疗方法,每年拯救全球超过12万例患者。但供器官短缺的现状,与器官移植技术和辅助药物的发展不匹配,制约了器官移植事业的发展。我国自2015年起已成为全球器官捐献和移植大国之一,2017年公民逝世后器官捐献数量超过5 000例,占全球捐献总量的15%以上。黄洁夫教授总结的器官捐献与移植"中国模式"得到了世界卫生组织、国际移植界的高度重视和充分肯定。本文通过整理全球及各国的器官捐献与移植数据,剖析全球现状与发展趋势,进一步探索我国公民器官捐献的影响因素并提出针对性的应对策略,以期实现我国器官捐献和移植的"自给自足"。 相似文献
43.
《Annals of hepatology》2019,18(2):397-401
We report the case of a 53-year-old-man who developed human T-cell leukemia virus type-1-associated myelopathy (HAM) after ABO-incompatible liver transplantation for alcoholic liver cirrhosis. The living donor was seropositive for human T-cell leukemia virus type-1 (HTLV-1) and the recipient was seronegative for HTLV-1 before transplantation. After transplantation, the recipient developed steroid-resistant acute cellular rejection, which was successfully treated using anti-thymocyte globulin, and he was eventually discharged. He underwent spinal surgery twice after the transplantation for the treatment of cervical spondylosis that had been present for a period of 9 months before the transplantation. The surgery improved his gait impairment temporarily. However, his gait impairment progressed, and magnetic resonance imaging revealed multiple sites of myelopathy. He was diagnosed with HAM 16 months after the transplantation. Pulse steroid therapy (1000 mg) was administered over a period of 3 days, and his limb paresis improved. Presently, steroid therapy is being continued, with a plan to eventually taper the dose, and he is being carefully followed up at our institution. Our case suggests that liver transplantation involving an HTLV-1-positive living donor carries the risk of virus transmission and short-term development of HAM after transplantation. 相似文献
44.
[摘要] 目的 探究HBV相关慢加急性肝衰竭(HBV-related acute-on-chronic liver failure, HBV-ACLF)患者血清中微小核糖核酸(microRNA, miR)-122和高迁移率族蛋白1(high-mobility group box-B1, HMGB1)水平及其与病情、预后的关系。方法 回顾性分析2016年1月—2018年1月我院收治的120例HBV-ACLF患者的一般及临床资料。根据临床结局,将患者分为存活组(53例)和死亡组(67例)。比较2组患者的一般资料、实验室检查指标及血清miR-122、HMGB1水平。多因素Logistic回归分析影响患者预后的因素。Pearson检验分析miR-122、HMGB1水平分别与TBIL、PA、终末期肝病评分模型(the model of end-stage liver disease score, MELD)评分的相关性。ROC曲线分析miR-122和HMGB1水平对患者的死亡预测价值,获得最佳临界值。根据临界值将患者分为A组、B组和C组,用Kaplan-Meier法绘制生存曲线,比较3组患者在3年随访期间的生存率。结果 存活组和死亡组患者的年龄、身体质量指数、并发症、病情分期、MELD评分、ALB、球蛋白、TBIL、ALT、AST、LDH、PT、PTA、HBV DNA、miR-122、HMGB1相比,差异均具有统计学意义(P均<0.05)。年龄、并发症、病情分期、MELD评分、TBIL、PT、PTA、miR-122、HMGB1均是影响患者预后的危险因素(P均<0.05)。miR-122、HMGB1水平分别与TBIL、MELD评分呈显著正相关,与PTA呈显著负相关(P均<0.05)。miR-122和HMGB1预测患者死亡的最佳临界值分别为31.42和14.56 μg/L。A组患者预后3年内生存率显著高于B组和C组(P均<0.05)。结论 miR-122和HMGB1水平与HBV-ACLF患者的病情和死亡预后密切相关,可间接反映患者的病情严重程度,在HBV-ACLF的诊断及预后中具有重要价值。 相似文献
45.
46.
47.
ObjectiveThe beneficial effects of carnitine supplementation on nonalcoholic fatty liver disease are unclear. We conducted a systematic review and meta-analysis to evaluate the effects of carnitine supplementation on liver function, lipid profile, body mass index, body weight, and homeostasis model assessment of insulin resistance in patients with nonalcoholic fatty liver disease.MethodsA comprehensive search of PubMed, Web of Science, Scopus, Cochrane Library, and Google Scholar databases were performed. Only randomized placebo-controlled human studies that examined the effects of carnitine supplementation on liver function, lipid profile, body mass index, body weight, and homeostasis model assessment of insulin resistance up to September 2019 were included. Fixed effects or random-effects models were applied to compute the pooled effect size. Heterogeneity assessments were performed using Cochran’s Q test and I-squared statistics. The quality of the studies was assessed using the Jaded scale.ResultsA total of 5 articles were selected, including 334 individuals (167 in control and 167 in intervention groups). The results demonstrated that carnitine supplementation significantly reduced homeostasis model assessment of insulin resistance (HOMA-IR) (WMD: −0.91; 95 % CI: −1.11, −0.72; p < 0.001, I2 = 0.0 %) and the levels of aspartate aminotransferase (AST) (WMD: −16.62; 95 % CI: −28.11, −5.14; IU/l; p = 0.005, I2 = 93.5 %), alanine aminotransferase (ALT) (WMD: -33.39; 95 % CI: −45.13, −21.66; IU/l; p < 0.001, I2 = 93.4 %), and triglycerides (TG) (WMD: −22.13; 95 % CI: −38.91, −5.34; mg/dl; p = 0.01; I2 = 0.0 %). However, the results of the pooled effect size did not show any significant effect of carnitine supplementation on body mass index (BMI) (WMD: 0.07; 95 % CI: −0.15, 0.29; p = 0.55; I2 = 0.0 %), body weight (WMD: −0.28; 95 % CI: −2.23, 1.68; p = 0.78; I2 = 45.7 %), the levels of gamma-glutamyl transferase (γGT) (WMD: −11.31; 95 % CI: −24.35, 1.73; IU/l; p = 0.09, I2 = 61.1 %), cholesterol (WMD: −13.58; 95 % CI: −46.77, 19.60; mg/dl; p = 0.42; I2 = 94.9 %), high-density lipoprotein-cholesterol (HDL-C) (WMD: 1.36; 95 % CI: −0.96, 3.68; mg/dl; p = 0.25; I2 = 64.7 %), and low density lipoprotein-cholesterol (LDL-C) (WMD: −14.85; 95 % CI: −45.43, 15.73; mg/dl; p = 0.34; I2 = 96.4 %).ConclusionsThis analysis shows that carnitine supplementation for patients with nonalcoholic fatty liver disease demonstrates a reduction in AST, ALT, TG levels and HOMA-IR. However, no significant effect of carnitine supplementation was observed on BMI, body weight, the levels of γGT, TC, HDL-cholesterol and LDL-cholesterol. 相似文献
48.
49.
50.